HUE042932T2 - Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra - Google Patents

Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra

Info

Publication number
HUE042932T2
HUE042932T2 HUE14705225A HUE14705225A HUE042932T2 HU E042932 T2 HUE042932 T2 HU E042932T2 HU E14705225 A HUE14705225 A HU E14705225A HU E14705225 A HUE14705225 A HU E14705225A HU E042932 T2 HUE042932 T2 HU E042932T2
Authority
HU
Hungary
Prior art keywords
inhibitor
cetp
prevention
treatment
pharmaceutical compositions
Prior art date
Application number
HUE14705225A
Other languages
English (en)
Inventor
John Ford
Patrick Round
John Kastelein
Atsuhiro Kawaguchi
Koichi Tomiyasu
Kozo Oka
Original Assignee
Dezima Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dezima Pharma B V filed Critical Dezima Pharma B V
Publication of HUE042932T2 publication Critical patent/HUE042932T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14705225A 2014-02-05 2014-02-05 Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra HUE042932T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14705225.2A EP3102212B1 (en) 2014-02-05 2014-02-05 Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
PCT/NL2014/050068 WO2015119495A1 (en) 2014-02-05 2014-02-05 Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases

Publications (1)

Publication Number Publication Date
HUE042932T2 true HUE042932T2 (hu) 2019-07-29

Family

ID=50116144

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14705225A HUE042932T2 (hu) 2014-02-05 2014-02-05 Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra

Country Status (32)

Country Link
US (4) US10653692B2 (hu)
EP (1) EP3102212B1 (hu)
JP (1) JP6263271B2 (hu)
KR (1) KR101967970B1 (hu)
CN (5) CN113332287A (hu)
AP (1) AP2016009359A0 (hu)
AR (1) AR099299A1 (hu)
AU (1) AU2014381733B2 (hu)
BR (1) BR112016018077A8 (hu)
CA (1) CA2938718C (hu)
CR (1) CR20160353A (hu)
CY (1) CY1121707T1 (hu)
DK (1) DK3102212T3 (hu)
EA (1) EA032689B1 (hu)
ES (1) ES2710104T3 (hu)
HR (1) HRP20190211T1 (hu)
HU (1) HUE042932T2 (hu)
IL (1) IL247037A (hu)
LT (1) LT3102212T (hu)
MA (1) MA39319A1 (hu)
ME (1) ME03295B (hu)
MX (1) MX369471B (hu)
PH (1) PH12016501548A1 (hu)
PL (1) PL3102212T3 (hu)
PT (1) PT3102212T (hu)
RS (1) RS58329B1 (hu)
SG (1) SG11201605956RA (hu)
SI (1) SI3102212T1 (hu)
TW (1) TWI651086B (hu)
UA (1) UA120922C2 (hu)
WO (1) WO2015119495A1 (hu)
ZA (1) ZA201605490B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3102212T1 (sl) 2014-02-05 2019-03-29 Dezima Pharma B.V. Zaviralec proteina za prenos holesterolnih estrov (CETP) in farmacevtski pripravki, ki obsegajo navedeni zaviralec, za uporabo pri zdravljenju ali preprečevanju srčno-žilnih bolezni
EP4218765A3 (en) * 2014-08-28 2023-08-09 NewAmsterdam Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
CA3210033A1 (en) * 2021-02-18 2022-08-25 Newamsterdam Pharma B.V. Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia
IL305576A (en) * 2021-03-05 2023-10-01 Newamsterdam Pharma B V Objetive for the treatment of dementia
WO2024009144A1 (en) 2022-07-05 2024-01-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
EA018734B1 (ru) * 2006-10-10 2013-10-30 Релайэнт Фармасьютикалз, Инк. СТАТИН И ОМЕГА-3 ЖИРНЫЕ КИСЛОТЫ ДЛЯ СНИЖЕНИЯ УРОВНЕЙ Apo-B
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
SI3102212T1 (sl) 2014-02-05 2019-03-29 Dezima Pharma B.V. Zaviralec proteina za prenos holesterolnih estrov (CETP) in farmacevtski pripravki, ki obsegajo navedeni zaviralec, za uporabo pri zdravljenju ali preprečevanju srčno-žilnih bolezni
EP4218765A3 (en) * 2014-08-28 2023-08-09 NewAmsterdam Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors

Also Published As

Publication number Publication date
CA2938718C (en) 2022-10-18
RS58329B1 (sr) 2019-03-29
EA032689B1 (ru) 2019-07-31
BR112016018077A8 (pt) 2020-06-23
AU2014381733B2 (en) 2020-09-03
EA201691572A1 (ru) 2016-12-30
KR101967970B1 (ko) 2019-04-10
CN113332287A (zh) 2021-09-03
KR20160146664A (ko) 2016-12-21
US20240024315A1 (en) 2024-01-25
ES2710104T3 (es) 2019-04-23
MX2016010212A (es) 2017-08-10
CN112755031A (zh) 2021-05-07
TW201613597A (en) 2016-04-16
ZA201605490B (en) 2018-05-30
AR099299A1 (es) 2016-07-13
US11013742B2 (en) 2021-05-25
UA120922C2 (uk) 2020-03-10
WO2015119495A1 (en) 2015-08-13
US20210228580A1 (en) 2021-07-29
PT3102212T (pt) 2019-02-06
EP3102212B1 (en) 2018-11-07
AP2016009359A0 (en) 2016-08-31
US11642344B2 (en) 2023-05-09
JP2017505333A (ja) 2017-02-16
EP3102212A1 (en) 2016-12-14
HRP20190211T1 (hr) 2019-04-05
MA39319A1 (fr) 2017-07-31
CN106232121A (zh) 2016-12-14
IL247037A (en) 2017-01-31
CN113332288A (zh) 2021-09-03
DK3102212T3 (en) 2019-02-11
CN110721187A (zh) 2020-01-24
PL3102212T3 (pl) 2019-05-31
ME03295B (me) 2019-07-20
US20200230138A1 (en) 2020-07-23
US20170182048A1 (en) 2017-06-29
NZ723645A (en) 2020-09-25
AU2014381733A1 (en) 2016-08-18
US10653692B2 (en) 2020-05-19
CY1121707T1 (el) 2020-07-31
SG11201605956RA (en) 2016-08-30
MX369471B (es) 2019-11-08
SI3102212T1 (sl) 2019-03-29
CA2938718A1 (en) 2015-08-13
BR112016018077A2 (pt) 2017-08-08
LT3102212T (lt) 2019-02-25
PH12016501548B1 (en) 2016-10-03
PH12016501548A1 (en) 2016-10-03
JP6263271B2 (ja) 2018-01-17
CR20160353A (es) 2017-06-23
TWI651086B (zh) 2019-02-21

Similar Documents

Publication Publication Date Title
IL252596A0 (en) History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL251834B1 (en) Pharmaceutical compositions containing peptide variants and methods of using them
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
HK1232120A1 (zh) 喹啉衍生物用於治療軟組織肉瘤的方法和用途以及用於治療軟組織肉瘤的藥物組合物
DK3335739T3 (en) Mussel adhesive protein product and the use thereof for the treatment of inflammation of the mucosa
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
ZA201702385B (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
IL248210A0 (en) Methods and preparations for the treatment of blood vessel malformations
MA40590A (fr) Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
PL3197556T3 (pl) KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
EP3261628A4 (en) Cholesteryl ester transfer protein (cetp) inhibition in the treatment of cancer
EP3225237A4 (en) Fatty acid amides for the prevention and/or treatment of steatohepatitis
EP3265108A4 (en) PEPTIDES AND COMPOSITIONS AS WELL AS USES THEREOF IN THE TREATMENT OF DISEASES
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
EP3219323B8 (en) Pharmaceutical composition for treatment and/or prevention of hepatitis c
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL243402A0 (en) Methods for identifying preparations for use in the treatment of heart diseases and the use of preparations for the treatment of these diseases
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same
GB201317059D0 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease